Determination of free insulin-like growth factor-I in human serum: comparison of ultrafiltration and direct immunoradiometric assay

被引:41
作者
Frystyk, J
Ivarsen, P
Stoving, RK
Dall, R
Bek, T
Hagen, C
Orskov, H
机构
[1] Aarhus Kommune Hosp, Inst Expt Clin Res, DK-8000 Aarhus C, Denmark
[2] Aarhus Kommune Hosp, Med Dept M, DK-8000 Aarhus, Denmark
[3] Aarhus Univ Hosp, Res Lab Nephrol & Hypertens, DK-8200 Aarhus N, Denmark
[4] Odense Univ Hosp, Med Dept M, DK-5000 Odense, Denmark
[5] Aarhus Univ Hosp, Dept Ophthalmol, DK-8000 Aarhus C, Denmark
关键词
D O I
10.1054/ghir.2001.0197
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Two fundamentally different methods are currently used for the determination of free insulin-like growth factor-I (IGF-I): ultrafiltration by centrifugation (UF) and direct immunoradiometric assay (IRMA). The aim was to evaluate a commercial IRMA (DSL, Webster, TX, USA) and to compare it with UF In the IRMA it is recommended that samples be incubated for 2 h at 5 degreesC. When comparing samples (n = 8) incubated for 1(3)/(4) and 2(1)/(4) h, levels increased by 27 +/- 5% (P < 0.0001). When incubating samples at 22*C instead of 5'C, levels increased by 1 92 32% (P < 0.000 1). Addition of IGF-binding protein-1 (IGFBP-1) to normal sera (n = 6) dose-dependently decreased ultrafiltered free IGF-I only (P < 0.0007). Similarly, UF was more sensitive than IRMA to addition of IGFBP-2 (P < 0.05). In healthy subjects (n = 35) IRMA yielded 20% higher levels than UF (1.09 +/-0.09 vs 0.91 +/-0.12 mug/L; P < 0.0001). IRMA and UF yielded similar results in healthy subjects treated with IGF-I (n = 5) or growth hormone (n = 7) and in acromegalic patients (n = 6) before and after somatostatin analogue treatment. However, marked differences were observed in conditions with elevated IGFBP-1 and -2. In type-1 diabetics (n = 23) ultrafiltered free IGF-I was more reduced than IRMA free lGF-I (38 +/-9 vs 76 +/-7% of matched controls (n = 13); P < 0.0001). In patients with chronic renal failure (n = 25), IRMA free IGF-I was identical to control levels (n = 13), whereas ultrafiltered free IGF-I was decreased by 51 +/-7% (P < 0.0001). Similarly, women with anorexia nervosa (n = 9) studied before and after weight gain showed significant changes in ultrafiltered free IGF-I only (P <less than> 0.03). In conclusion, IRMA was not very robust with respect to variations in sample incubation and this may bias results. IRMA generally yielded higher levels than UF, in accordance with the knowledge that IRMA measures free plus readily dissociable IGF-I. IRMA was less affected than UF by added IGFBP-1 and -2, and reductions in free IGF-I were better revealed by UF than IRMA. (C) 2001 Harcourt Publishers Ltd.
引用
收藏
页码:117 / 127
页数:11
相关论文
共 29 条
[1]   Multiple endocrine abnormalities of the growth hormone and insulin-like growth factor axis in patients with anorexia nervosa: Effect of short- and long-term weight recuperation [J].
Argente, J ;
Caballo, N ;
Barrios, V ;
Munoz, MT ;
Pozo, J ;
Chowen, JA ;
Morande, G ;
Hernandez, M .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (07) :2084-2092
[2]  
Bereket A, 1997, J PEDIATR ENDOCR MET, V10, P197
[3]   A SPECIFIC RADIOIMMUNOASSAY FOR INSULIN-LIKE GROWTH FACTOR-II - THE INTERFERENCE OF IGF BINDING-PROTEINS CAN BE BLOCKED BY EXCESS IGF-I [J].
BLUM, WF ;
RANKE, MB ;
BIERICH, JR .
ACTA ENDOCRINOLOGICA, 1988, 118 (03) :374-380
[4]   MEASUREMENT OF FREE HORMONES IN BLOOD [J].
EKINS, R .
ENDOCRINE REVIEWS, 1990, 11 (01) :5-46
[5]   FREE INSULIN-LIKE GROWTH-FACTORS (IGF-I AND IGF-II) IN HUMAN SERUM [J].
FRYSTYK, J ;
SKJAERBAEK, C ;
DINESEN, B ;
ORSKOV, H .
FEBS LETTERS, 1994, 348 (02) :185-191
[6]   FREE INSULIN-LIKE GROWTH-FACTORS IN HUMAN OBESITY [J].
FRYSTYK, J ;
VESTBO, E ;
SKJAERBAEK, C ;
MOGENSEN, CE ;
ORSKOV, H .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1995, 44 (10) :37-44
[7]  
Frystyk J, 1995, GROWTH REGULAT, V5, P169
[8]   The pharmacokinetics of free insulin-like growth factor-I in healthy subjects [J].
Frystyk, J ;
Hussain, M ;
Skjærbæk, C ;
Porksen, N ;
Froesch, ER ;
Orskov, H .
GROWTH HORMONE & IGF RESEARCH, 1999, 9 (02) :150-156
[9]  
Frystyk J, 1999, DIABETES-METAB RES, V15, P314, DOI 10.1002/(SICI)1520-7560(199909/10)15:5<314::AID-DMRR56>3.3.CO
[10]  
2-5